

- (ख) अगर निर्माताओं ने उपर्युक्त सारणी के स्तंभ (6) में वर्णित अधिकतम कीमत पर सरकार को वास्तव में भुगतान किया है या यह देय है तो वे वस्तु एवं सेवा कर को जोड़ सकते हैं।
- (ग) औषध (मूल्य नियंत्रण) आदेश, 2013 के पैराग्राफ 11 में दिए गए प्रावधानों के तहत निर्माताओं को उपर्युक्त सारणी के स्तंभ (6) में विनिर्दिष्ट खुदरा मूल्य के आधार पर अनुसूचित विनिर्मितियों के पैकों के लिए खुदरा मूल्य निर्धारित करें। निर्माता औषध (मूल्य नियंत्रण) आदेश, 2013 के पैराग्राफ 24 के तहत फॉर्म V में अधिसूचना की तारीख से एक मूल्य सूची एनपीपीए को आईपीडीएमएस के माध्यम से जारी करें तथा उसकी कापी राज्य औषधि नियंत्रकों और विनिर्माता वितरकों को जारी करें।
- (घ) औषध (मूल्य नियंत्रण) आदेश, 2013 के 24 (4) के अनुसार प्रत्येक फुटकर विक्रेता और वितरक विनिर्माता द्वारा दिए गए रूप में ऐसे परिसर, जहां कारबार को इस प्रकार किया जा रहा है कि उससे परामर्श के इच्छुक किसी व्यक्ति के लिए पहुंच आसान हो, वहां उसके किसी सुस्पष्ट भाग पर कीमत सूची और पूरक सूची, यदि कोई हो, को प्रदर्शित करेगा।
- (ङ) उपर्युक्त गैर अधिकतम कीमत (खुदरा मूल्य) केवल उपर्युक्त निर्माता/विपणन के लिए लागू है जैसा कि उन्होंने औषध (मूल्य नियंत्रण) आदेश, 2013 के तहत अनुबद्ध मूल्य निर्धारण/संशोधन के लिए फॉर्म I पर जमा किया गया था और सरकार द्वारा निर्धारित सभी लागू वैधानिक आवश्यकताओं की पूर्ति के अधीन प्रासंगिक विधियों/नियमों के अन्तर्गत जैसा कि केन्द्रीय/राज्य लाइसेंसिंग ऑथोरिटी के सक्षम प्राधिकारी द्वारा मेन्यूफेक्चरिंग लाइसेंस मंजूरी के तहत संबंधित विनिर्मित निर्माता/विपणन कम्पनियां जो अनुपालन करती हैं।
- (च) विनिर्माता या विपणन कम्पनी, उपरोक्त विनिर्मितियों और विनिर्दिष्ट शर्तों का पालन नहीं करती हैं तो वे आवश्यक वस्तुएँ अधिनियम, 1955 के साथ पठित डीपीसीओ, 2013 के प्रावधानों के अधीन ब्याज सहित अधिप्रभारित राशि को जमा करने के लिए दायी होंगे।
- (छ) इस आदेश में उपरोक्त तालिका के कॉलम (3) और (5) में तत्स्थानी प्रविष्टियों में निर्दिष्ट विनिर्माण और विपणन कंपनियों की स्ट्रेथ और नाम के साथ, उपरोक्त तालिका के कॉलम (2) में निर्दिष्ट ऐसे फॉर्मूलेशन के खुदरा मूल्य के निर्धारण के परिणामस्वरूप, कॉलम (2), (3) और (5) में तत्स्थानी प्रविष्टियों में यथा निर्दिष्ट उस विनिर्माण और विपणन कंपनियों के लिए निर्दिष्ट स्ट्रेथ के साथ फॉर्मूलेशन के खुदरा मूल्य को निर्धारित करने वाले कोई मूल्य आदेश यदि इस अधिसूचना से पहले जारी किए गए हो, तो उसे इसका स्थान लिया माना जाएगा।

[पीएन/248/116/2023/एफ/फा.सं. 8(116)/2023/डी.पी./एनपीपीए-डी.वी.-II]

महावीर सैनी, उप निदेशक (मूल्य निर्धारण)

## MINISTRY OF CHEMICALS AND FERTILIZERS

(Department of Pharmaceuticals)

(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)

### ORDER

New Delhi, the 15th September, 2023

**S.O. 4076(E).**—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

TABLE

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1	Rosuvastatin & Clopidogrel Capsules	Each hard gelatin capsule contains: <b>Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (as Pellets)</b> <b>Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets)</b>	1 Capsule	M/s Synokem Pharmaceuticals Ltd / M/s Torrent Pharmaceuticals Limited	18.95

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
2	Diclofenac Diethylamine, Methyl Salicylate and Menthol Gel	<b>Composition:</b> <b>Diclofenac Diethylamine IP 2.32 % w/w eq. to Diclofenac Sodium IP 2.0 % w/w</b> <b>Methyl Salicylate IP 10 % w/w</b> <b>Menthol IP 5 % w/w</b>	1 Gram	M/s Daiwik Pharmasphere Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd.	4.08
3	Linagliptin and Metformin Hydrochloride Tablets	<b>Each film coated tablet contains:</b> <b>Linagliptin 2.5mg</b> <b>Metformin Hydrochloride IP 500mg</b>	1 Tablet	M/s Exemed Pharmaceuticals / M/s Abbott Healthcare Pvt. Ltd.	8.97
4	Linagliptin + Metformin Hydrochloride Tablet	<b>Each film coated tablet contains:</b> <b>Linagliptin 2.5mg</b> <b>Metformin Hydrochloride IP 850mg</b>	1 Tablet	M/s Sai Primus Life Biotech Private Limited / M/s Primus Remedies Pvt. Ltd.	12.18
5	Linagliptin + Metformin Hydrochloride Tablet	<b>Each film coated tablet contains:</b> <b>Linagliptin 2.5mg</b> <b>Metformin Hydrochloride IP 1000mg</b>	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd.	9.60
6	Linagliptin + Metformin Hydrochloride Tablet	<b>Each film coated tablet contains:</b> <b>Linagliptin 2.5mg</b> <b>Metformin Hydrochloride IP 500mg</b>	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd.	8.97
7	Linagliptin + Metformin Hydrochloride Tablet	<b>Each film coated tablet contains:</b> <b>Linagliptin 2.5mg</b> <b>Metformin Hydrochloride IP 500mg</b>	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd.	8.97
8	Linagliptin + Metformin Hydrochloride Tablet	<b>Each film coated tablet contains:</b> <b>Linagliptin 2.5mg</b> <b>Metformin Hydrochloride IP 1000mg</b>	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd.	9.60
9	Linagliptin and Metformin Hydrochloride Tablets	<b>Each film coated tablet contains:</b> <b>Linagliptin 2.5mg</b> <b>Metformin Hydrochloride IP 1000mg</b>	1 Tablet	M/s Exemed Pharmaceuticals / M/s Abbott Healthcare Pvt. Ltd.	9.60
10	Pantoprazole Sodium (EC) & Levosulpiride (SR) Capsules	<b>Each Hard gelatine capsule contains:</b> <b>Pantoprazole Sodium Sesquihydrate IP eq. to Pantoprazole 40mg (As Enteric Coated Pellets)</b> <b>Levosulpiride 75mg (As Sustained Release Pellets)</b>	1 Capsule	M/s Lucent Biotech Limited / M/s Torrent Pharmaceuticals Ltd.	15.96
11	Budesonide and Formoterol Fumarate	<b>Each 2 ml respule contains:</b> <b>Budesonide IP 1mg</b> <b>Formoterol Fumarate Dihydrate eq. to Formoterol Fumarate 20 mcg</b>	Per 2 ml	M/s Axa Parenterals Ltd./ M/s J.B. Chemicals & Pharmaceuticals Ltd.	56.20
12	Itraconazole Capsules (Supra- Bioavailable Formulation)	<b>Each Hard gelatine capsule contains:</b> <b>(Supra-Bioavailable formulation)</b> <b>Itraconazole IP 130mg</b>	1 Capsule	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Dr. Reddy's Laboratories Limited	19.30
13	Linagliptin + Metformin Hydrochloride Extended Release Tablet	<b>Each film coated bilayer tablet contains:</b> <b>Linagliptin 2.5mg</b> <b>Metformin Hydrochloride (As extended release)IP 1000mg</b>	1 Tablet	M/s Exemed Pharmaceuticals / M/s Intas Pharmaceuticals Ltd.	9.60
14	Linagliptin + Metformin Hydrochloride Tablet	<b>Each film coated tablet contains:</b> <b>Linagliptin 2.5mg</b> <b>Metformin Hydrochloride IP 500mg</b>	1 Tablet	M/s Macleods Pharmaceuticals Ltd.	8.97
15	Linagliptin + Metformin Hydrochloride Tablet	<b>Each film coated tablet contains:</b> <b>Linagliptin 2.5mg</b> <b>Metformin Hydrochloride IP 1000mg</b>	1 Tablet	M/s Macleods Pharmaceuticals Ltd.	9.60
16	Linagliptin + Metformin Hydrochloride (ER)	<b>Each film coated bilayered tablet contains:</b> <b>Linagliptin 2.5mg</b>	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Cipla Ltd.	9.60

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
	Tablet	<b>Metformin Hydrochloride IP 1000mg (as Extended release)</b>			
17	Itraconazole Capsules (Supra- Bioavailable Formulation)	<b>Each Hard gelatine capsule contains: (Supra-Bioavailable formulation) Itraconazole IP 65mg</b>	1 Capsule	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Dr. Reddy's Laboratories Limited	10.81
18	Diclofenac Potassium & Metaxalone Tablets	<b>Each uncoated tablet contains: Diclofenac Potassium IP 50mg Metaxalone USP 400mg</b>	1 Tablet	M/s Windlas Biotech Limited / M/s Intas Pharmaceuticals Ltd.	15.08
19	Cefuroxime Axetil & Potassium Clavulanate Tablets	Each film coated tablet contains: Cefuroxime Axetil IP eq. to Cefuroxime 500mg Potassium Clavulanate Diluted IP Eq. to Clavulanic Acid 125mg	1 Tablet	M/s Hetero Labs Limited / M/s Sun Pharmaceuticals Industries Limited	55.23
20	Levosulbutamol and Ipratropium Bromide respule solution	<b>Each 2.5ml contains: Levosalbutamol Sulphate IP eq. to Levosalbutamol 1.25mg Ipratropium Bromide IP eq. to Ipratropium (anhydrous) 500mcg</b>	1 ML	M/s AXA Parenterals Ltd. / M/s Mankind Pharma Ltd.	5.49
21	Moxifloxacin Eye Drops	<b>Composition: Moxifloxacin hydrochloride IP eq. to Moxifloxacin 0.5% w/v Preservative : Benzalkonium Chloride Solution IP 0.02% w/v</b>	1 ML	M/s East African (India) Overseas / M/s Torrent Pharmaceuticals Limited	17.00
22	Pantoprazole Dual Release Gastro Resistant Tablets	<b>Each Dual Release Gastro Resistant Tablet Contains: Pantoprazole Sodium IP eq. to Pantoprazole 80mg</b>	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd. / M/s Mankind Pharma Ltd.	15.30
23	Telmisartan, Chlorthalidone & Cilnidipine tablets	<b>Each film coated tablet contains: Telmisartan IP 40mg Chlorthalidone IP 6.25mg Cilnidipine IP 10mg</b>	1 Tablet	M/s Macleods Pharmaceuticals Ltd.	13.05
24	Povidone Iodine Gargle	Composition: Povidone Iodine IP 0.5% w/v (available Iodine 0.05% w/v)	1 ml	M/s Pontika Aerotech Limited / M/s Emcure Pharmaceuticals Limited	0.70
25	Teneligliptin, Pioglitazone and Metformin Hydrochloride (as Sustained Release) Tablets	<b>Each Film coated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg Metformin Hydrochloride IP 500mg (as Sustained Release)</b>	1 Tablet	M/s Synokem Pharmaceuticals Limited / M/s Micro Labs Limited	16.07
26	Teneligliptin, Pioglitazone and Metformin Hydrochloride (as Sustained Release) Tablets	<b>Each Film coated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg Metformin Hydrochloride IP 1000mg (as Sustained Release)</b>	1 Tablet	M/s Synokem Pharmaceuticals Limited / M/s Micro Labs Limited	17.85
27	Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet	<b>Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form)</b>	1 Tablet	M/s Mascot Health Series Pvt. Ltd. / M/s Intas Pharmaceuticals Ltd.	16.06

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
28	Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet	Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form)	1 Tablet	M/s Mascot Health Series Pvt. Ltd. / M/s Eris Lifesciences Limited	16.06
29	Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet	Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd.	16.06
30	Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet	Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticals Ltd.	16.09
31	Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet	Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s La Renon Healthcare Private Limited	16.09
32	Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet	Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form)	1 Tablet	M/s Mascot Health Series Pvt. Ltd. / M/s Intas Pharmaceuticals Ltd.	17.13
33	Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet	Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form)	1 Tablet	M/s Mascot Health Series Pvt. Ltd. / M/s Eris Lifesciences Limited	17.13
34	Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet	Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd.	17.13
35	Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released)	Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticals Ltd.	17.16

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
	Tablet	<b>Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form)</b>			
36	Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet	<b>Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form)</b>	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s La Renon Healthcare Private Limited	17.16
37	Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets	<b>Each film coated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride IP (as Sustained Release) 500mg</b>	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd.	18.00
38	Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets	<b>Each uncoated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 500mg</b>	1 Tablet	M/s Exemed Pharmaceuticals / M/s Alkem Laboratories Limited	16.29
39	Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets	<b>Each film coated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride IP (as Sustained Release) 1000mg</b>	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd.	19.00
40	Dapagliflozin, Sitagliptin and Metformin Hydrochloride (ER) Tablets	<b>Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg (As Extend Release form)</b>	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Alkem Laboratories Limited	14.59
41	Dapagliflozin, Sitagliptin and Metformin Hydrochloride (ER) Tablets	<b>Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50mg Metformin Hydrochloride IP 500mg (As Extend Release form)</b>	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Alkem Laboratories Limited	13.62
42	Linagliptin + Metformin Hydrochloride Extended Release Tablet	<b>Each film coated bilayer tablet contains: Linagliptin 5mg Metformin Hydrochloride (As extended release) IP 1000mg</b>	1 Tablet	M/s Exemed Pharmaceuticals / M/s Intas Pharmaceuticals Ltd.	14.37
43	Linagliptin + Metformin	<b>Each film coated bilayered tablet contains:</b>	1 Tablet	M/s Synokem Pharmaceuticals Ltd. /	14.37

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
	Hydrochloride (ER) Tablet	<b>Linagliptin 5mg Metformin Hydrochloride IP 1000mg (as Extended release)</b>		M/s Cipla Ltd.	
44	Linagliptin + Metformin Hydrochloride (ER) Tablet	<b>Each film coated tablet contains: Linagliptin 5mg Metformin Hydrochloride (as Extended release) IP 1000mg</b>	1 Tablet	M/s Exemed Pharmaceuticals Ltd. / M/s Micro Labs Ltd.	14.37
45	Linagliptin + Metformin Hydrochloride (ER) Tablet	<b>Each film coated bilayered tablet contains: Linagliptin 5mg Metformin Hydrochloride (as Extended release) IP 1000mg</b>	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd.	14.00
46	Linagliptin + Metformin Hydrochloride (ER) Tablet	<b>Each film coated bilayered tablet contains: Linagliptin 5mg Metformin Hydrochloride (as Extended release) IP 1000mg</b>	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Lupin Limited	14.37
47	Metoprolol Succinate Extended Release, Amlodipine 5mg & Telmisartan Tablet	<b>Each film coated bilayered tablet contains: Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate 50mg (As Extended release) Amlodipine Besilate IP IP eq. to Amlodipine 5mg Telmisartan IP 40mg</b>	1 Tablet	M/s Ajanta Pharma Limited	14.23
48	Ambroxol Hydrochloride, Salbutamol Sulphate, Guaiphenesin & Methol Liquid	<b>Each 5ml contains: Ambroxol Hydrochloride IP 15mg Salbutamol Sulphate IP eq. to Salbutamol 1mg Guaiphenesin IP 50mg Methol IP 1mg</b>	1 ml	M/s Naxpar Pharma Pvt. Ltd. / M/s Geno Pharmaceuticals Pvt. Ltd.	0.52
49	Glimepiride & Lobeglitazone Sulfate tablet	<b>Each uncoated Bilayer tablet contains: Lobeglitazone Sulfate 0.5mg Glimepiride IP 1mg</b>	1 Tablet	M/s Glenmark Pharmaceuticals Limited	11.39
50	Combikit of Clarithromycin Tablets IP, Esomeprazole Tablets IP & Amoxicillin Tablets USP	<b>Each Strip contains: A. Clarithromycin Tablets IP 2 Tablets Each film coated tablet contains: Clarithromycin IP 500mg B. Esomeprazole Tablets IP 2 Tablets Each Enteric coated tablet contains: Esomeprazole Magnesium Trihydrate IP eq. to Esomeprazole 40mg C. Amoxicillin Tablets USP 2 Tablets Each Film coated tablet contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 1000mg</b>	Each Strip	M/s Malik Lifesciences Pvt. Ltd. / M/s Cipla Limited	151.98
51	Brinzolamide, Brimonidine Tartrate & Timolol Ophthalmic suspension	<b>Each ml contains: Brinzolamide IP 10mg Brimonidine Tartrate IP 2 mg Timolol Maleate eq. to Timolol IP 5 mg Water for injection</b>	1 ml	M/s Micro labs Limited	105.25

**Note:**

- (a) The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

- (b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.

[PN/248/116/2023/F/F. No. 8(116)/2023/D.P./NPPA-Div.-II]

MAHAVEER SAINI, Dy. Director (Pricing)

#### आदेश

नई दिल्ली, 15 सितम्बर, 2023

**का.आ. 4077(अ).**—जबकि, (i) पाइपेरासिलिन 2 ग्राम + टैज़ोबैक्टम 250 मिलीग्राम और (ii) पाइपेरासिलिन 4 ग्राम + टैज़ोबैक्टम 500 मिलीग्राम डीपीसीओ 2013 की अनुसूची- I के तहत एक निर्धारित विनिर्मिती है और इसकी अधिकतम कीमत तय है।

और जबकि, मेसर्स गुफिक बायोसाइंसेज लिमिटेड ने (i) टैज़ोफिक इंजेक्शन 2.25 ग्राम जिसमें पाइपेरासिलिन 2 ग्राम + टैज़ोबैक्टम 250 मिलीग्राम है और (ii) टैज़ोफिक इंजेक्शन 4.5 ग्राम जिसमें पाइपेरासिलिन 4 ग्राम + टैज़ोबैक्टम 500 मिलीग्राम है जिसे दोहरे कक्ष की विशेषता वाले बैग जिसमें विभिन्न सोलुसन को देने से पहले अलग रखने की व्यवस्था है जो दवा देने के समय में कमी, सही खुराक का आश्वासन, अस्पताल संदूषण से बचने, उच्च स्थिरता और सुविधा प्रदान करने आदि में सहायक है।

और जबकि, विशेषज्ञों की बहु-विषयक समिति ने दिनांक 11.09.2022 और 11.07.2023 की अपनी 45वीं और 52वीं बैठक में पाया कि मेसर्स गुफिक बायोसाइंसेज लिमिटेड के (i) टैज़ोफिक इंजेक्शन 2.25 ग्राम जिसमें पाइपेरासिलिन 2 ग्राम + टैज़ोबैक्टम 250 मिलीग्राम है और (ii) टैज़ोफिक इंजेक्शन 4.5 ग्राम जिसमें पाइपेरासिलिन 4 ग्राम + टैज़ोबैक्टम 500 मिलीग्राम है जिसे दोहरे कक्ष की विशेषता वाले बैग जो दवा देने के समय में कमी, सही खुराक का मिश्रण और संदूषण में कमी में सहायक है।

और जबकि, विशेषज्ञों की बहु-विषयक समिति ने सिफारिश की थी कि मेसर्स गुफिक बायोसाइंसेज लिमिटेड को दोहरे कक्ष की विशेषता वाले बैग के लिये (i) पाइपेरासिलिन 2 ग्राम + टैज़ोबैक्टम 250 मिलीग्राम और (ii) पाइपेरासिलिन 4 ग्राम + टैज़ोबैक्टम 500 मिलीग्राम की अधिकतम कीमत से 15% की वृद्धि की अनुमति दी जाए।

और जबकि, एनपीपीए ने अपनी 116वीं प्राधिकरण बैठक दिनांक 06.09.2023 में विशेषज्ञों की बहु-विषयक समिति की सिफारिश को स्वीकार करने का निर्णय लिया है।

अतः औषध (मूल्य नियंत्रण) आदेश, 2013 के पैरा 11 के उप पैरा (3) और (4) द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए का.आ. 1394(अ) दिनांक 30 मई, 2013 का.आ. 5249 (अ) दिनांक 11 नवंबर, 2022 को रसायन और उर्वरक मंत्रालय, भारत सरकार द्वारा जारी किया गया था, जहां तक यह (i) टैज़ोफिक इंजेक्शन 2.25 ग्राम जिसमें पाइपेरासिलिन 2 ग्राम + टैज़ोबैक्टम 250 मिलीग्राम है और (ii) टैज़ोफिक इंजेक्शन 4.5 ग्राम जिसमें पाइपेरासिलिन 4 ग्राम + टैज़ोबैक्टम 500 मिलीग्राम है जो दोहरे कक्ष की